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Critical step of Rociletinib synthesis, regioselective nucleophilic aromatic substitu-
tion of C-2 chlorine at pyrimidine molecule 3 with amine 2, was optimised by implemen-
tation of pre-DoE screening and DoE-based algorithms. The synthesis reaction was de-
veloped and optimised by following a quality by design (QbD) approach, whereby a 
control strategy was developed for enhanced level of quality assurance. Optimisation of 
three main parameters (volume of solvent mixture, solvent ratio, and NaOAc quantity) 
resulted with good isomer ratio of over 8:1 with respect to desired C-2 isomer 4 with 
minimum of di-substituted impurity 6. The crude product was, however, contaminated 
with Zn-based inorganics and had to be recrystallized to achieve acceptable purity and 
assay. Interaction of process variables and their corresponding effects on the percent 
conversion of maleic acid were discussed. Consistency of statistical model was verified 
by analysis of variance (ANOVA). API quality specifications (purity, impurity levels) are 
described across the modelling of process space, which was defined through quality tar-
get specifications (conversion NLT 70 %; Product Compound 4 NLT 50 %, Impurity 5 
NMT 20 %, and Impurity 6 NMT 0.5).
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Introduction
As it is known, 5-fluoromethylpyrimidine de-
rivatives are often used as key raw materials in the 
development of pharmaceutical products, mainly as 
various kinase inhibitors.1–3
Pyrimidine nucleosides containing a trifluoro-
methyl group at 5-position are known to have sig-
nificant biological activity.4 Fluorinated nucleosides 
and their analogues represent the class of organoflu-
orine compounds, which found an extensive appli-
cation in the 70’s in biological chemistry, life-sci-
ence, and medicine branches.5,6 The anti-tumor 
activity of 5-fluorouracil and 5-trifluoromethylura-
cil derivatives is also reported.7–9
Capecitabine (Xeloda1) is the first FDA-ap-
proved oral chemotherapy drug for the treatment of 
both metastatic breast cancer and colorectal cancer, 
two of the most frequent solid malignancies world-
wide. Capecitabine is now extensively prescribed in 
clinical oncology. This fluoropyrimidine has been 
designed as a less toxic and more specific alterna-
tive to canonical 5-Fluorouracil (5-FU).10
Rociletinib 1 is a novel, oral, targeted covalent 
(irreversible) mutant-selective inhibitor of the can-
cer-causing mutant forms of epidermal growth fac-
tor receptor (EGFR). It was designed to selectively 
target both the initial activating EGFR mutations 
and the dominant acquired T790M resistance muta-
tion. Rociletinib is a new chemical entity that con-
tains 5-trifluoro-2,4-diaminopyrimidine moiety as a 
critical structure motif (Fig. 1a).
Pyrimidines are known to be attacked by nucle-
ophiles at positions C-2 and C-4 of pyrimidine ring. 
Many examples for nucleophilic substitution reac-
tions of 2,4-dichloropyrimidine having a variety of 
substituents at 5-position (e. g. F, Cl, Br, I, CH3, 
CH3O, CN) with amines and alcohols, are known to 
result preferentially with 4-substituted aminopyrim-
idines. Interestingly, 5-trifluoro substituted pyrimi-
dines provide almost 1:1 mixture of 2-amino and 
4-amino product. The primary factors that influence 
selectivity of this addition are electronically nega-
tive nature of trifluoromethyl group accompanied 
by steric bulkiness. Trifluromethyl group is block-
ing the approach of a negatively charged nucleop-
hile to the sterically hindered 4-position.11–14 As pre-
viously reported, addition of Lewis acids (e. g. 
ZnCl2) improved the regioselectivity in favour of 
substitution at the 2-postion.11,15–17 This reaction is 
described in several patents and articles, published 
by different authors.11,18–21 The theory is that Zn 
complexes with the pyrimidine N-3 nitrogen, thus 
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directing chemistry to the less hindered site, to C-2. 
In this way, with appropriate solvent(s) and base, 
one could gain high isomer ratio with respect to de-
sired C-2 isomer. Richter et al. from Pfizer present-
ed a good review on this topic.11 They tested a se-
ries of Lewis acids, and ZnCl2 gave the most 
selective result. In the mixture of DCE/t-BuOH and 
Et3N as a base (t-BuOH seemed to be quite import-
ant for regioselectivity), 10:1 isomer ratio (in favour 
of C-2 isomer) was obtained. Although Lewis acid 
should be present in catalytic amount, o-substituted 
anilines, particularly o-methoxy group at anilines 
(such as in compound 2) are involved in a chelating 
effect with the Lewis acid, so ZnCl2 should be pres-
ent even with 2 mol Eqs to obtain good selectivity. 
Even then, the reaction takes 24 hours to reach 
completion compared to typical 2–4 hours with an-
ilines while selectivity is usually 5:1. Crystalliza-
tion can be obtained due to moderate selectivity. 
Thus, firstly, ZnCl2 must form a complex with py-
rimidine 3 and then with o-methoxy substituted an-
iline 2. Base should be involved to gain satisfactory 
conversion and regioselectivity (and added last, if 
possible).
A series of initial experiments have been per-
formed, reaction conditions, solvents and bases 
have been tested (with or without the presence of 
ZnCl2) to achieve the best isomer ratio: the best ini-
tial result was obtained with K2CO3 as a base, in the 
presence of ZnCl2 in combination of CPME and 
t-BuOH as solvents – ratio 14:1 in favour of C-2 
isomer was obtained, although the reaction was not 
completed.
In the development and optimization of this 
step there were several challenges; one of them was 
analytics. Following reaction kinetics was difficult 
because compound 3 was unstable in analytical 
conditions, and isomer compound 5 was reacting in 
the vial with compound 2 giving di-substituted 
compound 6 as an impurity (Fig. 1c). Therefore, re-
action was usually carried out overnight (min. 20 h) 
and analysed afterwards.
The other major challenge was isolating pure 
compound 4 from the reaction mixture. Reaction 
takes place in the mixture of solvents in which com-
pound 2 and compound 4 are not soluble, so isola-
tion by extraction was not an option. One of the 
solvents was t-BuOH, which crystallizes at lower 
temperatures or in vacuo, so filtration in its pres-
ence was also not viable – although some attempts 
of filtration were done after the removal of t-BuOH 
by distillation. Such filtered crude cake consisted of 
compound 4, its impurities (mostly 5 and 6) and 
lots of inorganics – preferably ZnCl2 and its hydro-
lytic products – and it had to be purified in the pres-
ence of water in which all the inorganics would be 
dissolved.
The application of Design of Experiments 
(DoE) approach to chemical development has been 
successfully used for several years.22 More recently, 
the practice has been acknowledged by regulatory 
agencies within the concept of Quality by Design 
(QbD),23 and it is becoming the base of any well-de-
fined process development strategy within the in-
dustry. DoE Study is conducted with the purpose to 
estimate the effect of Critical Process Parameters 
(CPPs) and their interactions on relevant Critical 
Quality Attribute (CQA), and to determine optimum 
and robust conditions. CPP is a process parameter 
whose variability has an impact on a critical quality 
attribute (CQAs) and therefore should be monitored 
or controlled to ensure the process produces the de-
sired quality.
(a) (b) (c)
F i g .  1  – Chemical structure of: a) Rociletinib 1, b) regioselective nucleophilic aromatic substitution of C-2 chlorine at pyrimidine 
molecule 3 with 2 to give an amine 4 as major product and amine 5 as minor product, and c) di-substituted impurity 6
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Experimental
Materials
Amine 2 was produced in our laboratory by in-
ternal synthetic method. 5-CF3-2,4-dichloropyrimi-
dine 3 was supplied by Angene International Ltd. as 
high purity grade. All reagents and solvents were 
provided by Sigma-Aldrich or Merck, and were of 
reagent grade.
Analytical methods
Method for reaction monitoring and chromato-
graphic purity: Instrument. Agilent 1260/1290 or 
equivalent Column & Packing: Acquity UPLC BEH 
C18, 2.1×100 mm, 1.7 µm Buffer: 10 mM KH2PO4 
pH = 3.5 (pH adjusted with phosphoric acid) Mo-
bile phase: A: Buffer, B: Acetonitrile gradient: 0. 
min – 95 % A, 20. min – 20 % A, 25. min – 10 % 
A, 25.01. min – 95 % A, 28. min – 95 % A Run 
time: 28 min Flow rate: 0.4 mL min–1 Injection vol-
ume: 1.0 µL Detector: 210 (BW 4 nm) Column 
temperature: 40 °C Autosampler temperature: 10 °C 
Diluent: acetonitrile:water 8:2. The process devel-
opment in PLIVA was supported by Analytical De-
partment, which is in accordance with highest phar-
maceutical standards, such as GMP, GLP, etc. All 
analytical methods were developed and validated.
1H (500 MHz) and 13C (500 MHz) NMR spec-
tra were recorded for pyridine solutions at room 
temperature using Bruker DRX500MHz spectrome-
ter. Peak assignments were aided by 1H-1H COSY, 
HMBC and HSQC experiments.
Statistical methods (DoE, QbD)
Pre-DoE screening of all factors (parameters) 
on twolevels is conducted to determine CPPs and 
generally to reduce number of factors. Solvent 
choice is screened through principal component 
analysis (PCA). Range of process parameters is im-
portant (wide vs. narrow region), in process screen-
ing the wider range is used, while in late phase the 
narrower range in which product quality (defined 
by specifications of CQAs, for example impurities 
within control range) can be guaranteed. Ranges are 
also affected by downstream of the process (for ex-
ample purification factor of isolation to meet speci-
fications, etc.). DoE characterization of reduced 
number of factors on three levels is conducted to 
optimize reaction conditions in a systematic way to 
gain information about linear, interaction, and cur-
vilinear effects. In general, QbD supports product 
robustness evaluations, product enhancement, as 
well as product troubleshooting. Pre-DoE as a 
screening, and QbD is supported through in depth 
knowledge of process.
Synthesis
Final procedure for preparation of 
1-(4-(4-((4-chloro-5-(trifluoromethyl)pyrimidin- 2-yl)
amino)-3-methoxyphenyl) piperazin-1-yl)ethanone (5)
A one-litre reactor was thermostated to 20–25 
°C, and t-BuOH (277.5 mL) and ZnCl2 (37.70 g, 
0.277 mol) were charged. MTBE (277.5 mL) was 
added and reaction mixture was stirred at 20–25 °C 
for 1 hour (until colourless solution was obtained). 
Compound 3 (19.57 mL, 0.145 mol) was added and 
mixture was stirred at 20–25 °C for 1 hour to allow 
compound 3 to form a complex with zinc. Pow-
dered NaOAc (11.34 g, 0.138 mol) was added and 
reaction mixture was stirred for one more hour at 
20–25 °C. Finally, compound 2 (34.47 g, 0.138 
mol) was added and reaction mixture (yellow sus-
pension) was stirred at 20–25 °C for 20 hours. Upon 
cooling to 0 °C, water (300 mL) was slowly added 
dropwise to maintain the temperature at 0–5 °C 
(thus preventing hydrolysis of pyrimidine chlorine). 
After all water was added, MTBE and t-BuOH were 
distilled off at diminished pressure (bath tempera-
ture max. 45 °C) and acetonitrile (300 mL) was 
added into the remaining suspension. The yellow 
suspension obtained had a pH value of 3.5 and it 
was adjusted to 5 with 25 % ammonium hydroxide 
solution. Reaction mixture was warmed up to 70 °C 
when it dissolved. It was slowly cooled to 0 °C to 
initiate crystallization (seeding optional). The re-
sulting suspension was stirred for 18 hours at 0 °C, 
filtered off and the solid was washed with a cold 
mixture of acetonitrile/water 1:1 cold mixture 
(2×120 mL) and dried at 65 °C/150 mbar/16 h 
yielding 51.33 g (86 %) of crude compound 5 (pu-
rity by UPLC: 95.13 area %, assay: 64.6 %). Crude 
compound 5 was purified by recrystallization as fol-
lows: 5 (45 g, 0.105 mol) was suspended in 450 mL 
ACN/water 1:1 mixture and warmed up to reflux 
temperature while stirring. Hot mixture (thin sus-
pension) was filtered to remove traces of inorganics 
and the filtrate was warmed up again to 75 °C. Ob-
tained solution was stirred at 75 °C for 20 minutes 
and cooled to 45–50 °C to initiate crystallization. It 
was stirred at 45–50 °C for 1 hour, then cooled to 
20–25 °C and stirred overnight, cooled to 0 °C, 
stirred for 2 more hours and filtered off. Solid was 
washed with 45 mL ACN/water 1:1 cold mixture 
and dried at 65 °C/150 mbar/16 h to yield 29.25 g 
(65 %) of crystalline compound 5 (purity by UPLC: 
99.65 area %, assay: 100.2 %).
Results and discussion
Pre-DoE screening
Screening of Lewis acids and content of ZnCl2
Solubility of Zn compounds depends on the 
temperature and pH of the water in question. For 
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example, at pH<5, ZnCl2 is stable. At neutral pH, 
Zn2+ in water is insoluble because it converts to 
Zn(OH)2. Solubility increases with increasing acidi-
ty. Above pH 11, solubility also increases. Zinc dis-
solves in water as ZnOH+(aq) or Zn2+(aq). Exam-
ples of solubility of zinc compounds are: ZnCl2 
4320 g L–1 and ZnO or ZnSO4∙7H2O 580 g L
–1etc.24,25 
Unfortunately, anionic ZnCO3 generated from 
K2CO3 has a solubility of 0.21 g L
–1– and when 
K2CO3 was used as a base – depending on its quan-
tity and pH of the reaction mixture, we often ended 
up with huge amounts of insoluble ZnCO3 which 
we could not remove until the final synthesis step. 
All intermediates and final Rociletinib have very 
low solubility and are hard to purify from inorgan-
ics. Therefore, we had to change the base to one 
which would (in case of significant change of pH) 
form a water-soluble Zn salt. Besides ZnCl2, which 
gave satisfactory results regarding regioselectivity, 
LiCl resulted in the opposite selectivity, while MgBr2 
did not form a complex with compound 3 at all.
As mentioned previously, although Lewis acid 
should be present in catalytic amount, o-methoxy 
group at compound 2 is also involved in a chelating 
effect with the Lewis acid, so ZnCl2 should be pres-
ent with 2 mol Eqs to obtain good selectivity. For 
confirmation, reactions with no ZnCl2 added result-
ed in low selectivity, even in benefit to C-4 isomer 
(in acidic conditions, main product is di-substituted 
pyrimidine 6), and 1.2 mol Eq of ZnCl2 was still not 
enough to gain a good selectivity.
Screening of solvents
Initial screening of solvents gave different re-
sults (Table 1). The main goal was to achieve good 
conversion, acceptable isomer ratio of C-4 and C-2 
isomers and minimizing impurities as well. In the 
attempt to find the right reaction, solvent principal 
vector method was applied. A principal component 
analysis (PCA) is a way to picture the structure of 
the data as completely as possible by using as few 
variables as possible, and for that purpose statistical 
software is used (JMP 12.0). More than 120 differ-
ent solvents and their combinations were searched 
according to their physical characteristics, i.e. melt-
ing points, boiling points, dielectric constants, re-
fractive indexes, empirical polarity parameters, den-
sities, lipophilicities and solubilities in water. The 
eigenvalues represent a partition of the total varia-
tion in the multivariate sample. Most important pa-
rameters were related with polarity and lipophilicity 
(with eigenvalues of 3.11 and 2.85 which represents 
66.25 % of cumulative percentage of the behaviour 
explained for the eigenvectors). Non-polarity and 
non-lipophilicity of solvent was desired.
Also, pseudo components for mixtures (MT-
BE/t-BuOH = 1/1) based on molar ratio were used. 
PCA statistical analysis was performed and all as-
cending candidates were suggested. The main prob-
lems with group of candidates were: their reactivity 
(amines such as morpholine, TEA), high melting 
point (dioxane), low boiling point (diethylether), 
and safety (diisopropylether, benzene). Table 1 
presents final results of statistical analysis of sol-
vents and combinations of solvents which would 
give the best C-4:C-2 isomer ratio. Following the 
results shown above, an extended experimental re-
search was applied to find the right solvent or com-
bination of solvents. Selection of results obtained 
using different solvents and their mixtures in vari-
ous volume ratios are presented in Table 2. The best 
obtained results were in 1/1 mixtures of CPME (cy-
clopentylmethyl ether)/t-BuOH and MTBE/t-BuOH. 
The final choice was MTBE/t-BuOH due to the 
lower boiling point of MTBE (easy to remove if/
when needed) and its lower price. Although a huge 
number of experiments have been performed using 
CPME/t-BuOH in various ratios and volumes, from 
this point, mainly experiments with MTBE/t-BuOH 
will be discussed.
Ta b l e  1  – Results of different solvents used for principal 
component analysis (PcA) by JMP
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Screening of bases
In Table 3, only results from CPME/t-BuOH 
1/1 and MTBE/t-BuOH 1/1 mixtures are shown. 
The best choice of base regarding regioselectivity 
was the use of powdered K2CO3. Isomer ratio with 
respect to C-2 isomer was 14:1 although conversion 
was rather slow and reaction mixture had to be 
warmed up to 50 °C to achieve >90 % conversion. 
The second choice was t-BuOK, but it generated 
degradation impurities. All other bases gave lower 
isomer ratio (Table 3). Since the exclusion of K2CO3 
due to generation of insoluble ZnCO3, the focus be-
came finding another viable base, which would 
generate soluble salts, such as NaOAc. Conversion 
is 95 % if reaction is carried out with NaOAc (1.05 
mol Eq), in MTBE/t-BuOH 1/1 (16–20 V), at 25 °C 
for 20 hours. Besides, temperature increase results 
information of di-substituted impurity 6, which is 
generated in the reaction between isomer 5 and 
amine 2 rather than between compound 4 and 
amine 2.
Design of Experiments
From the pre-DoE experiments, it was conclud-
ed that three main parameters (volumes and ratios 
of MTBE/t-BuOH and mol Eqs of NaOAc) affect 
the overall product quality. The final screening de-
sign (JMP 12.0.) was chosen for factor screening. 
Table 4 shows the ranges of process parameters in 
main DoE characterization of three process parame-
ters. The combination of continuous two-level cate-
gorical factors with central point replications was 
used to describe active two-factor interactions 
which exhibit strong curvature.
Volumes and ratio of MTBE/t-BuOH
Table 4 presents the results obtained using dif-
ferent volumes and ratios of MTBE/t-BuOH mix-
ture. All experiments were done on 20-g batches 
using 2.00 mol Eq ZnCl2.
Content of NaOAc and order of addition
Content of NaOAc varied from 1.00 to 1.50 
mol Eq which was part of JMP12 design of experi-
ments. Change in NaOAc content in the reaction 
mixture can be seen in Table 4.
Ta b l e  2  – Experimental pre-DoE screening of candidate solvents
Entry Solvent (V m–1) Base (mol Eq)




1 THF, 40 V Et3N 1.20 89.74 47.51 : 38.04 : hidden
2 DMA, 50 V NMM 1.10 94.67 30.37 : 52.46 : 1.84
3 ACN, 50 V K2CO3 1.10 70.65 41.37 : 21.98 : 0.38
4 DCM, 50 V K2CO3 1.10 83.37 64.13 : 5.07 : 0.98
5 2-PrOH, 50 V K2CO3 1.10 94.85 63.94 : 19.34 : 1.38
6 CPME, 50 V Et3N 1.10 92.23 63.50 : 25.86 : hidden
7 MTBE, 20 V K2CO3 1.10 52.17 39.09 : 2.21 : 0.53
8 t-BuOH, 20 V K2CO3 1.10 64.85 38.85 : 5.62 : 5.58
9 DME/t-BuOH 1:1.25 V K2CO3 1.10 97.03 70.41 : 21.89 : 2.77
10 MTBE/EtOH 1:1.20 V K2CO3 1.10 75.00 41.08 : 14.75 : 1.33
11 MTBE/2-PrOH 1:1.20 V K2CO3 1.10 59.59 42.32 : 8.20 : 1.13
12 MTBE/t-BuOH 1:1.20 V K2CO3 1.10 97.36 73.58 : 5.10 : 15.48
13 CPME/t-BuOH 1:1.15 V K2CO3 1.10 95.55 74.78 : 6.46 : 4.32
Ta b l e  3  – Experimental pre-DoE screening of bases (solvent 
cPME/t-BuoH, 50 V m–1, ZnCl2 2.20 mol Eq)
Entry Base (mol Eq)
Conversion  




1 K2CO3 1.10 86.52 58.02 : 4.10 : 0.83
2 Et3N 1.10 99.24 46.26 : 40.84 : 5.48
3 DIPEA 1.10 86.07 69.74 : 7.02 : 2.29
4 NMM 1.10 41.73 8.51 : 4.62 : 0.22
5 NaH 1.10 74.35 48.17 : 7.38 : 0.71
6 t-BuOK 1.10 88.74 58.44 : 7.17 : 1.24
7 K3PO4 1.10 90.53 60.09 : 18.48 : 8.98
8 KOH 1.10 85.66 61.69 : 2.79 : 10.09
9 NaOAc 1.10 98.17 82.71 : 7.96 : 1.79
10 KOAc 1.05 81.41 63.61 : 7.37 : 2.34
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The main conclusion is that excess NaOAc has 
no significant impact on the reaction profile, al-
though hydrolytic impurities may increase. Con-
versely, the lack of base results in low conversion. 
Thus, 1 mol Eq of NaOAc is enough to complete 
the reaction, which is also confirmed by design of 
experiments (Fig. 2). NaOAc also has to be used in 
powdered form to enable the highest possible con-
version. Different approaches regarding order of ad-
dition of reagents and starting compounds have also 
been tested. Anion generation at compound 2 fol-
lowed by addition of previously prepared compound 
3/ZnCl2 complex is not an option, since low isomer 
ratio is obtained in combination with slower con-
Ta b l e  4  – Final DoE with critical 3 parameters (Custom Design with minimal number of experiments)
Entry MTBE/t-BuOH (V m–1) MTBE/t-BuOH ratio
NaOAc
(mol Eq)




1 10 1:1 1.50 96.14 70.00 : 9.83 : 1.54
2 10 5:1 1.00 89.92 28.22 : 25.59 : 0.28
3 18.5 1:1 1.05 94.34 75.73 : 9.02 : 0.61
4 20 1:1 1.05 89.61 66.25 : 10.57 : 0.28
5 20 3:1 1.25 71.19 46.30 : 25.70 : 0.19
6 30 1:1 1.00 89.89 69.93 : 7.62 : 0.61
7 30 5:1 1.50 25.00 13.91 : 4.13 : 0.00
8 20 1:1 0.00 46.56 30.41 : 2.92 : 0.82
9 18.5 1:1 1.05 95.53 76.29 : 8.28 : 1.89
10 18.5 1:1 1.05 95.38 77.17 : 8.52 : 2.33
F i g .  2  – Actual vs. predicted plot with summary of fit (RSq, R2 and Root Mean Square Error, RMSE)
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version. In case when NaOAc was added 1 h after 
compound 2, isomer ratio was lower (cca 6:1). The 
best isomer ratio was obtained when compound 2 
was added 1 hour after addition of NaOAc to the 
complex; isomer compound 5 remained < 2 % and 
di-substituted compound 6 was cca 5 %. However, 
the material was heterogeneous, impure, and had to 
be recrystallized. Recrystallization was carried out 
in ACN/water 1/1 (20 V) in average 64 % yield giv-
ing overall yield of cca 54 %. The optimization of 
three parameters: volume of solvent, ratio of sol-
vents, and content of NaOAc resulted in highest 
value of desirability – acceptable overall conver-
sion, isomer ratio and content of di-substituted im-
purity (although isomer ratio was higher using high-
er volumes (Table 4, Raw 6)). The Standard Least 
Squares statistical model approach fits a wide spec-
trum of standard models that include regression, 
analysis of variance, analysis of covariance, and 
mixed models, as well as the models typically used 
(a) (b)
(c) (d)
F i g .  3  – Prediction profiler contour plot: a) RSA for mixture of MTBE/t-BuoH and mol Eq of NaoAc, b) volumes and mol Eq of 
NaoAc, c) mixture of MTBE/t-BuoH and mol Eq of NaoAc, and d) surface profiler
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to analyse designed experiments. In this paper, 
models are associated with experimental design and 
involve interaction and quadratic terms. To under-
stand how each variable fit predicted the response, 
basic statistic is presented in Fig. 2. R2 in all re-
sponses is > 0.97 (except in the case of Impurity 6 
in which it is > 0.91).
In commercial process development, it is im-
portant to describe process parameter space in as 
little time as possible. For that purpose, custom de-
sign is used because of its flexibility. Process pa-
rameter investigation is made where the parameters 
were varied – main effects plus their interaction 
with one central point (default 12 experiments), but 
minimal number of experiments (Table 4 – 8 exper-
iments) was used. Statistical power on individual 
parameters is between 0.4 – 0.6, which is signifi-
cantly lower than 0.8 which is recommended for 
statistical analysis. Since the minimal number ex-
periments are used there is some confounding be-
tween interactions of parameters. Replications (Ta-
ble 4, Row 9, on 20-g scale batch, and Table 4, Row 
10, on 35-g scale batch) were conducted to validate 
process optimal conditions and show reproducibili-
ty of methods used in this paper.
Analytic results are supported by compelling 
dynamic visualization tools, such as 2D contour 
plots profilers. These visual displays stimulate, 
complement, and support your understanding of the 
model. They enable optimisation of several respons-
es simultaneously, and investigation of the effect of 
noise (Fig. 3). Prediction profiler with maximum 
desirability set for a Response Surface Analysis, 
RSA shows the result of the most desirable settings. 
Finding maximum desirability is an iterative pro-
cess comprised of four different responses, two to 
maximize, Conversion and Product – Compound 4 
and two to minimize, impurity 4 and 5, and three 
factors (critical process parameters). Optimal reac-
tion conditions calculated in JMP12 were 18.5 vol-
umes of 1/1 mixture of MTBE/t-BuOH and 1.05 
mol Eq of NaOAc. Fig. 3 shows the area (white sur-
face) where optimum can be achieved: >80 % con-
version, >50 % of product, Compound 4, <12 % of 
C-4 isomer, impurity 5 and <1 % of di-substituted 
impurity 6. The contour profiler is useful for view-
ing response surfaces graphically, especially when 
there are multiple responses as a part of QbD initia-
tive. Model predictions were verified via results ob-
tained in the laboratory by replications of optimal 
conditions, and the experiments showed good agre-
ement with results obtained by statistical model.
In order to interpret the interaction of different 
process variables and their corresponding effect, 
contour plots were drawn (Fig. 3). The clear peaks 
of contour in Figs. 3a, 3b, 3c indicate that the opti-
mum operating conditions are exactly within the 
design boundary (conversion NLT 70 %; Product 
Compound 4 NLT 50 %, Impurity 5 NMT 20 %, 
and Impurity 6 NMT 0.5). The combined effect of 
two independent variables on the response is well 
illustrated by two-dimensional response surface by 
maintaining remaining variable at fixed level.
Conclusions
– Pre-DoE screening of solvents by principal 
vector method was applied.
– Principal component analysis-most import-
ant parameters for good conversion and good regi-
oselectivity were non-polarity and non-lipophilici-
ty-chosen MTBE and t-BuOH combination.
– Screening of bases was performed experi-
mentally and NaOAc was chosen as the most ap-
propriate base regarding conversion, regioselectivi-
ty and simplicity of removal during isolation.
– The final design of experiments (JMP 12.0) 
was performed for process realized experimentally, 
thus confirming that the best conversion and regi-
oselectivity was achieved by applying MTBE/t-
BuOH solvent mixture in 1/1 volume ratio, 16–18 
V m–1 and 1 mol Eq of NaOAc. Reaction was carried 
out by complexation of compound 3 (1.05 mol Eq) 
with ZnCl2 (2.00 mol Eq), followed by addition 
of NaOAc, and finally addition of compound 2 
(1.00 mol Eq) after one hour.
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